Chemotherapy Drugs Categorized as ‘In-Office Ancillary Services’

Publication
Article
OncologyONCOLOGY Vol 15 No 4
Volume 15
Issue 4

Not only has the Health Care Financing Administration (HCFA) backed off on threats to reduce Medicare and Medicaid payments to oncologists for in-office chemotherapy infusion drugs, but now HCFA is making it clear that oncologists can

Not only has the Health Care Financing Administration (HCFA)backed off on threats to reduce Medicare and Medicaid paymentsto oncologists for in-office chemotherapy infusion drugs, but now HCFA is makingit clear that oncologists can provide those drugs to patients without runningafoul of federal self-referral rules. Those rules actually became law in 1993thanks to Rep. Pete Stark (D-Calif), who sponsored the bill that made it illegalfor physicians to refer patients for 10 categories of medical services if thephysician or a member of his family had a financial interest in that serviceprovider. An exception was made for physicians referring patients intra-officefor ancillary services, but when HCFA issued the proposed rule a few years ago,it was unclear whether chemotherapy drugs would be included in the exemption.When HCFA issued the final rules this past January, it was clearly explainedthat chemotherapy infusion drugs were to be considered exempt.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Related Content